Stromal vascular fraction

Phase 2Small molecule

AAssistance Publique Hopitaux De Marseille

Stromal vascular fraction is one of 89 small molecule programs targeting Xerostomia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaActive, not recruiting

Systemic SclerosisActive, not recruiting

SclerodermaActive, not recruiting

XerostomiaPhase 1/Phase 2

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

SclerodermaPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

3 2

Actemra

Roche

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Ofev

Boehringer Ingelheim

Phase 3

1 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalActive, not recruiting

Stem Cells

NCT07405840

Clinical

Trials by Indication[1]

Treatment1 trial

Stem Cell Treatment of Peyronie´s Disease.

Completed·EEsbjerg Hospital - University Hospital of Southern Denmark·Phase 1·NCT04771442·22 enrolled

Intraarticular1 trial

The Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal-Vascular Fraction of Adipose Tissue Cells for Treatment of Knee Joint Arthrosis

Unknown status·SSwiss Medica XXI Century S.A.·Phase 2·NCT04050111·30 enrolled

Skin Regeneration1 trial

The Effect of Autologous Stromal Vascular Fractions on Skin Regeneration

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 1/2·NCT03189628·30 enrolled

Skin1 trial

The Improving Effect of Autologous Stromal Vascular Fraction (SVF) in Adipose Tissue on Skin Grafting

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 1/2·NCT02546882·75 enrolled

Systemic Sclerosis1 trial

Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis

Terminated·AAssistance Publique Hopitaux De Marseille·Phase 2·NCT02558543·40 enrolled

5 more indications

Xerostomia1 trial

Stromal Vascular Fraction for Treatment of Xerostomia

Withdrawn·MMidwestern Regional Medical Center·Phase 1/2·NCT03061110

Scleroderma1 trial

SCLERoderma et Adipose-DErived Stroma Cells

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 2·NCT02866552·44 enrolled

Efficacy1 trial

Efficacy of Stromal Vascular Fraction on Acne Scar Correction

Not yet recruiting·SSeoul National University Hospital·N/A·NCT07094958·16 enrolled

Crohn Disease1 trial

An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF

Completed·AAssistance Publique Hopitaux De Marseille·Phase 1/2·NCT02520843·10 enrolled

Stem Cells1 trial

Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage

Active, not recruiting·CClinical Center of Vojvodina·Phase 4·NCT07405840·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Stromal vascular fraction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stromal vascular fraction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stromal vascular fraction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique Hopitaux De Marseille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique Hopitaux De Marseille

Stromal vascular fraction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Treatment1 trial

Intraarticular1 trial

Skin Regeneration1 trial

Skin1 trial

Systemic Sclerosis1 trial

Xerostomia1 trial

Scleroderma1 trial

Efficacy1 trial

Crohn Disease1 trial

Stem Cells1 trial

References

Drug Info

Quick Facts

Related News